China demands halt to use of drugs containing recalled ingredient
The National Health Commission on Monday required medical institutions of all kinds and levels to stop using medicines containing the active ingredient valsartan produced by a domestic pharmaceutical company and to assist with related recalls.
The recall is due to an impurity involving the contaminant N-nitrosodimethylamine (NDMA), which was detected in the active pharmaceutical ingredients for valsartan, used to treat high blood pressure and heart failure.
Medical institutions must not use the recalled drugs containing impurity-affected valsartan during diagnosis and treatment, said a statement by the NHC, which added that medical personnel should take efficient measures to ensure medical safety.
The statement also asked medical institutions to keep local medical authorities and regulators informed about their work on assisting with the recall and halting use of the recalled drugs.
The producer, Zhejiang Huahai Pharmaceutical Co Ltd, halted shipments and launched voluntary recalls in domestic and foreign markets after it reported discovery of NDMA traces in its products for export to the drug regulator on July 6.